000			01944 a2200541 4500
005			20250516051854.0
264		0	_c20120110
008			201201s 0 0 eng d
022			_a1476-5500
024	7		_a10.1038/cgt.2011.45 _2doi
040			_aNLM _beng _cNLM
100	1		_aBhattacharyya, M
245	0	0	_aAn oncolytic adenovirus defective in pRb-binding (dl922-947) can efficiently eliminate pancreatic cancer cells and tumors in vivo in combination with 5-FU or gemcitabine. _h[electronic resource]
260			_bCancer gene therapy _cOct 2011
300			_a734-43 p. _bdigital
500			_aPublication Type: Journal Article; Research Support, Non-U.S. Gov't
650	0	4	_aAdenocarcinoma _xdrug therapy
650	0	4	_aAdenoviruses, Human _xgenetics
650	0	4	_aAnimals
650	0	4	_aAntineoplastic Agents _xtherapeutic use
650	0	4	_aCell Line, Tumor
650	0	4	_aCell Survival
650	0	4	_aCombined Modality Therapy
650	0	4	_aCytopathogenic Effect, Viral
650	0	4	_aDeoxycytidine _xanalogs & derivatives
650	0	4	_aFluorouracil _xtherapeutic use
650	0	4	_aGene Deletion
650	0	4	_aGene Expression Regulation, Viral _xdrug effects
650	0	4	_aHumans
650	0	4	_aKaplan-Meier Estimate
650	0	4	_aMice
650	0	4	_aMice, Inbred C57BL
650	0	4	_aMice, Nude
650	0	4	_aOncolytic Virotherapy
650	0	4	_aOncolytic Viruses _xgenetics
650	0	4	_aPancreatic Neoplasms _xdrug therapy
650	0	4	_aReceptors, Virus _xmetabolism
650	0	4	_aRetinoblastoma Protein _xmetabolism
650	0	4	_aVirus Replication _xgenetics
650	0	4	_aXenograft Model Antitumor Assays
650	0	4	_aGemcitabine
700	1		_aFrancis, J
700	1		_aEddouadi, A
700	1		_aLemoine, N R
700	1		_aHalldén, G
773	0		_tCancer gene therapy _gvol. 18 _gno. 10 _gp. 734-43
856	4	0	_uhttps://doi.org/10.1038/cgt.2011.45 _zAvailable from publisher's website
999			_c21080909 _d21080909